title: Topical thalidomide gel in oral chronic GVHD and role of in situ cytokine expression in monitoring biological activity.
authors.forename: L
authors.initials: L
authors.lastname: St John
authors.forename: S M
authors.initials: SM
authors.lastname: Gordon
authors.forename: R
authors.initials: R
authors.lastname: Childs
authors.forename: M
authors.initials: M
authors.lastname: Marquesen
authors.forename: S Z
authors.initials: SZ
authors.lastname: Pavletic
authors.forename: T X
authors.initials: TX
authors.lastname: Wu
authors.forename: T
authors.initials: T
authors.lastname: Cozzarelli
authors.forename: E
authors.initials: E
authors.lastname: Schroeder
authors.forename: M G
authors.initials: MG
authors.lastname: Saria
authors.forename: J M
authors.initials: JM
authors.lastname: Fall-Dickson
mesh_terms: D000287:Administration, Topical; D000328:Adult; D002908:Chronic Disease; D016207:Cytokines / Q000096:biosynthesis*; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D005786:Gene Expression Regulation / Q000187:drug effects*; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage*; D014184:Transplantation, Homologous
chemical_list: D016207:Cytokines; D005782:Gels; D007166:Immunosuppressive Agents; D013792:Thalidomide